To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________ FORM 10-K ____________________________________ ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 27-484269 ...

Travere Therapeutics Corporate Overview February 2026 Forward-Looking Statements This presentation contains forward-looking statements, including but not limited to statements about: continued progress with the FILSPARI launch in IgAN; statements regarding our products and products in development as potential foundational treatments and/or treatment standards; additional development and regulatory milestones, including expected data from additional studies and the expected timing thereof; plans and expectat ...

Core Viewpoint - Travere Therapeutics, Inc. will report its fourth quarter and full year 2025 financial results on February 19, 2026, after the U.S. financial markets close [1] Financial Reporting - The financial results will be discussed during a conference call and webcast scheduled for 4:30 p.m. ET on the same day [1] - Access to the webcast and dial-in information will be available on the Investor page of Travere's website [1]

Core Viewpoint - Travere Therapeutics (TVTX) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ending December 2025, which could significantly influence its stock price depending on the actual results compared to estimates [1][2]. Earnings Expectations - The consensus estimate for quarterly earnings is $0.03 per share, reflecting a year-over-year increase of +104.1% [3]. - Expected revenues are projected to be $142.46 million, representing a 90.5% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 17.07% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Travere is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +775.01%, suggesting a bullish outlook on the company's earnings [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of a potential earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Stocks with a positive Earnings ESP and a solid Zacks Rank have historically produced a positive surprise nearly 70% of the time [10]. Historical Performance - In the last reported quarter, Travere was expected to post a loss of $0.31 per share but instead reported earnings of $0.28, resulting in a surprise of +190.32% [13]. - Over the past four quarters, the company has exceeded consensus EPS estimates three times [14]. Conclusion - Travere is positioned as a compelling candidate for an earnings beat, but investors should consider other factors that may influence stock performance beyond earnings results [17].

Summary of Travere Therapeutics Conference Call Company Overview - **Company**: Travere Therapeutics (NasdaqGM:TVTX) - **Focus**: Rare diseases, specifically targeting IgA nephropathy, FSGS, and homocystinuria (HCU) [2][3] Key Points Product Development and Regulatory Updates - **FILSPARI**: - Launched for IgA nephropathy, aiming to replace traditional treatments like RAS inhibitors and ARBs [3] - Achieved record commercial performance in the last quarter, marking the strongest quarter to date [3] - sNDA under review for FSGS, with a PDUFA date extended to April 13, 2026, due to additional information requests from the FDA [3][6] - Anticipated to be the first approved treatment for FSGS, addressing a significant unmet need [3][6] - **HCU**: - Manufacturing challenges resolved, with plans to restart Phase III HARMONY study [4] - HCU is a genetic metabolic disease with significant health risks if untreated, including cognitive and psychiatric defects [34][35] Market Dynamics and Competitive Landscape - **FSGS Market**: - High confidence in the approvability of sparsentan for FSGS due to strong clinical trial results [6][10] - Anticipated rapid uptake post-approval, driven by urgency and prior experience with FILSPARI in IgA nephropathy [12][31] - Expectation of complementary therapies rather than direct competition in the FSGS space [19] - **IgA Nephropathy**: - Increased competition in the market, but Travere believes that the introduction of new therapies will expand the overall market rather than diminish FILSPARI's growth [21][22] - Observing a trend towards earlier treatment and combination therapies in line with updated treatment guidelines [22] Financial Position and Future Outlook - **Financial Health**: - End of year cash position at $323 million, sufficient to support ongoing operations and product launches without immediate capital needs [45][46] - **Long-term Strategy**: - Plans to pursue additional assets post-FSGS approval, focusing on synergies with existing development and commercial expertise [43][44] Other Important Insights - **Patient Compliance**: High persistence rates observed for FILSPARI, attributed to its once-daily dosing and positive patient outcomes [27] - **REMS Program**: Adjustments to the REMS program have positively impacted prescribing behavior, allowing for quarterly testing instead of monthly [28][29] - **Payer Dynamics**: Early indications show payers are supportive of combination therapies, which may enhance FILSPARI's market position [24][25] Conclusion Travere Therapeutics is positioned for significant growth with its focus on rare diseases, particularly with the anticipated approval of FILSPARI for FSGS. The company is well-capitalized and strategically planning for future developments while navigating a competitive landscape in the rare disease market.

Company Overview - Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for individuals with rare kidney and metabolic diseases in the United States [2]. Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere, specifically whether the company and certain executives made materially false and/or misleading statements or omitted material information regarding Travere's business and operations [1][2]. Law Firm Background - Robbins Geller is recognized as one of the leading law firms in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in securities-related class action cases in 2024, which is more than the next five law firms combined [3].

Company Overview - Travere Therapeutics is a San Diego-based biopharmaceutical company focused on rare kidney and metabolic diseases [1] - The company's key product, FILSPARI (sparsentan), is fully approved for IgA Nephropathy (IgAN) [1] Product Pipeline - FILSPARI is expected to receive a PDUFA decision on January 13, 2026, for its application in treating focal segmental glomerulosclerosis (FSGS) [1]

Company Overview - Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for individuals with rare kidney and metabolic diseases in the United States [2]. Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws related to Travere, specifically whether the company and certain executives made materially false and/or misleading statements or omitted material information regarding Travere's business and operations [1][2]. Law Firm Background - Robbins Geller is recognized as one of the leading law firms in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in securities-related class action cases in 2024, which is more than the next five law firms combined [3]. - The firm has been ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years for achieving the most monetary relief for investors [3]. - Robbins Geller has a significant history of obtaining large securities class action recoveries, including the largest ever recovery of $7.2 billion in the Enron Corp. securities litigation [3].

Core Viewpoint - Block & Leviton is investigating Travere Therapeutics, Inc. for potential securities law violations following a significant drop in its stock price after the FDA extended the review timeline for its drug application [1][2]. Group 1: Company Overview - Travere Therapeutics, Inc. experienced a trading halt after its shares fell over 30% on January 13, 2026, due to the FDA's extension of the review timeline for the supplemental New Drug Application for FILSPARI [2]. - The FDA set a new PDUFA target action date of April 13, 2026, citing that additional responses from Travere constituted a major amendment and required further data to assess clinical benefit [2]. Group 2: Investigation Details - Block & Leviton is examining whether Travere Therapeutics adequately disclosed the risks associated with the review extension and if prior communications regarding the regulatory timeline were misleading [2][4]. - The firm is open to representing investors who have lost money in Travere's stock, regardless of whether they have sold their shares [3][4]. Group 3: Investor Actions - Investors who have incurred losses are encouraged to contact Block & Leviton for potential recovery options [5]. - Whistleblowers with non-public information about Travere Therapeutics are invited to assist in the investigation, with the possibility of receiving rewards from the SEC [6]. Group 4: Firm Credentials - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].